Reckitt Benckiser Group Earnings Calls
| Release date | Mar 05, 2026 |
| EPS estimate | $0.499 |
| EPS actual | $0.499 |
| Revenue estimate | 9.9B |
| Revenue actual | 9.9B |
| Revenue Surprise | 0.00001010120804% |
| Release date | Jun 30, 2025 |
| EPS estimate | $0.443 |
| EPS actual | $0.381 |
| EPS Surprise | -13.90% |
| Revenue estimate | 9.56B |
| Revenue actual | 9.513B |
| Revenue Surprise | -0.492% |
| Release date | May 02, 2025 |
| EPS estimate | - |
| EPS actual | - |
| Revenue estimate | - |
| Revenue actual | - |
| Release date | Dec 31, 2024 |
| EPS estimate | $0.392 |
| EPS actual | $0.101 |
| EPS Surprise | -74.14% |
| Revenue estimate | 9.105B |
| Revenue actual | 8.76B |
| Revenue Surprise | -3.78% |
Last 4 Quarters for Reckitt Benckiser Group
Below you can see how RBGLY performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Dec 31, 2024 |
| Price on release | $12.52 |
| EPS estimate | $0.392 |
| EPS actual | $0.101 |
| EPS surprise | -74.14% |
| Date | Price |
|---|---|
| Dec 24, 2024 | $12.54 |
| Dec 26, 2024 | $12.55 |
| Dec 27, 2024 | $12.60 |
| Dec 30, 2024 | $12.49 |
| Dec 31, 2024 | $12.52 |
| Jan 02, 2025 | $12.46 |
| Jan 03, 2025 | $12.55 |
| Jan 06, 2025 | $12.47 |
| Jan 07, 2025 | $12.53 |
| 4 days before | -0.166% |
| 4 days after | 0.0832% |
| On release day | -0.499% |
| Change in period | -0.0831% |
| Release date | May 02, 2025 |
| Price on release | $14.02 |
| EPS estimate | - |
| EPS actual | - |
| Date | Price |
|---|---|
| Apr 28, 2025 | $13.11 |
| Apr 29, 2025 | $13.29 |
| Apr 30, 2025 | $13.45 |
| May 01, 2025 | $13.45 |
| May 02, 2025 | $14.02 |
| May 05, 2025 | $13.88 |
| May 06, 2025 | $14.02 |
| May 07, 2025 | $13.88 |
| May 08, 2025 | $13.58 |
| 4 days before | 6.91% |
| 4 days after | -3.12% |
| On release day | -1.41% |
| Change in period | 3.57% |
| Release date | Jun 30, 2025 |
| Price on release | $14.30 |
| EPS estimate | $0.443 |
| EPS actual | $0.381 |
| EPS surprise | -13.90% |
| Date | Price |
|---|---|
| Jun 24, 2025 | $14.46 |
| Jun 25, 2025 | $14.40 |
| Jun 26, 2025 | $14.30 |
| Jun 27, 2025 | $14.22 |
| Jun 30, 2025 | $14.30 |
| Jul 01, 2025 | $14.45 |
| Jul 02, 2025 | $14.31 |
| Jul 03, 2025 | $14.55 |
| Jul 07, 2025 | $14.32 |
| 4 days before | -1.08% |
| 4 days after | 0.146% |
| On release day | 1.02% |
| Change in period | -0.94% |
| Release date | Mar 05, 2026 |
| Price on release | $15.39 |
| EPS estimate | $0.499 |
| EPS actual | $0.499 |
| Date | Price |
|---|---|
| Feb 27, 2026 | $16.64 |
| Mar 02, 2026 | $16.64 |
| Mar 03, 2026 | $16.47 |
| Mar 04, 2026 | $16.20 |
| Mar 05, 2026 | $15.39 |
| Mar 06, 2026 | $14.83 |
| Mar 09, 2026 | $14.88 |
| Mar 10, 2026 | $14.68 |
| Mar 11, 2026 | $14.54 |
| 4 days before | -7.51% |
| 4 days after | -5.52% |
| On release day | -3.64% |
| Change in period | -12.62% |
Reckitt Benckiser Group Earnings Call Transcript Summary of Q4 2025
Reckitt delivered a solid 2025 with Core Reckitt like-for-like net revenue up 5.2% (volumes +1.5%, price/mix +3.7%) and group adjusted operating profit up 5.3% (constant currency). Growth was led by Emerging Markets (Core Reckitt EM up 14.6%), while Europe remained tough and North America showed resilient nonseasonal performance. Core Reckitt margins expanded 90 bps to 26.7%; Emerging Markets margin expanded 210 bps to 20.9%. The Fuel for Growth program delivered material fixed-cost savings and enabled stepped-up brand investment (BEI), while CapEx was increased to GBP 592m to strengthen supply chain and manufacturing capacity. The company completed the Essential Home divestment, returned GBP 2.3bn to shareholders (including a GBP 1.6bn special dividend), and continues to consider strategic options for Mead Johnson (which grew net revenues 3.8%). Guidance for 2026: Core Reckitt like-for-like net revenue growth of 4–5% (led by Emerging Markets), a temporary leverage uptick toward ~2.5x net debt/EBITDA by mid-year, continued Fuel for Growth delivery to largely offset stranded costs from the divestment, and an ambition for long-term sustainable EPS growth despite near-term dilution from the Essential Home transaction. Key priorities for 2026 include scaling Emerging Markets penetration and nascent categories, premiumization and omnichannel execution in developed markets, continued R&D-driven innovation (notably the first FDA-approved NDA for Mucinex 12-hour Cold & Fever), and continued investment in supply chain/localization and digitization.
Sign In
Buy RBGLY